Takeda could sell Shire drug candidate to clear antitrust hurdle

29 October 2018
mergers-acquisitions-big

Takeda Pharmaceutical (TSE: 4502) has confirmed it is discussing with the European Union the possibility of offloading Shire’s (LSE: SHP) SHP647 and certain associated rights, as a way of avoiding overlap with its gastroenterology portfolio.

In a statement, the Japanese firm said it had suggested to the European Commission (EC), the EU’s executive branch, that it could divest the Phase III candidate, after its proposed acquisition of the London-listed firm completes.

The move would avoid a clash with Entyvio (vedolizumab), which Takeda describes as “the cornerstone” of its specialty gastrointestinal portfolio. Shire is testing SHP647 against Crohn’s disease and ulcerative colitis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical